Introduction
============

Leber's hereditary optic neuropathy (LHON; OMIM [535000](http://www.ncbi.nlm.nih.gov/omim/?term=535000)) is an inherited neuropathy caused by primary mtDNA mutations leading to bilateral optic atrophy \[[@r1],[@r2]\]. As a result, visual prognosis is poor with the majority of patients with LHON registered as legally blind. This profound loss of vision in affected subjects is due to the targeted destruction of the highly specialized retinal ganglion cells (RGCs) \[[@r3]\]. Patients with LHON usually present initially with painless, subacute loss of vision in one eye, with the second eye becoming affected in the following weeks to months.

LHON has a prevalence of 1 in 31,000 in northern England, 1 in 39,000 in the Netherlands, and 1 in 50,000 in Finland \[[@r4]-[@r6]\]. The disease typically affects a young demographic, with peak onset between the ages of 15 and 30 years \[[@r7]\]. Patient carriers of LHON mutations who have not experienced any loss of vision before age 50 are likely not to do so.

However, several patients with LHON have suffered visual failure from as young as 2 years and as old as 87 years of age \[[@r8]\]. LHON demonstrates distinctive clinical signs, such as incomplete penetrance and an obvious gender bias with approximately 50% of male carriers and only 10% of female carriers developing the disease \[[@r9]\], suggesting that other genetic factors and/or the environment must play a role in disease penetrance \[[@r10]-[@r12]\].

Approximately 95% of those diagnosed with LHON have one of three primary mitochondrial mutations affecting complex I subunits of the respiratory chain---G3460A (A52T of ND1), G11778A (R340H of ND4), and T14484C (M64V of ND6) \[[@r13]-[@r15]\]---while other rare mutations (such as G13730A, G14459A, C14482G, A14495G, C14498T, C14568T, and T14596A) account for the final 5% \[[@r16]-[@r23]\]. LHON specifically targets the RGCs that are highly susceptible to oxidative stress and mitochondrial dysfunction \[[@r3]\]. Interestingly, some visual recovery can occur in patients with LHON, but the extent of this recovery is dependent upon the mutation involved in that patient's LHON. The point mutation T14484C exhibits some visual recovery in (58%) of patients with LHON, followed by the point mutation G3460A at 25%. Patients who harbour the G11778A mutation have the lowest level of visual recovery \[[@r24]-[@r27]\].

Current diagnostic strategies for the three most common mutations that cause LHON include individual endpoint PCR-restriction fragment length polymorphism (RFLP) \[[@r28]\], multiplex PCR-RFLP \[[@r29]\], allele-specific PCR \[[@r30]\], real-time PCR \[[@r31]\], and PCR followed by Sanger sequencing or pyrosequencing \[[@r32]\]. A targeted next-generation sequencing (NGS) panel is available for mitochondrial sequencing (mtSEEK®), and open source bioinformatics software is also available for extracting mitochondrial sequences from NGS exome sequences \[[@r33]\]. This study aimed to develop a novel multiplex closed tube real-time assay to detect the three common mutations using a combination of allele-specific amplification and high-resolution melt curve analysis. The assay will allow diagnostic laboratories to avoid costly NGS for most LHON cases.

Methods
=======

Patient DNAs were obtained from the Centre for Medical Genetics, Our Lady's Hospital for Sick Children, Dublin, Ireland and Oxford Medical Genetics Laboratories, Oxford, UK. Subjects gave written consent for the testing of their DNA for the 3 primary mutations causing LHON. All subject samples used in this study were previously tested for the 3 primary mutations using simplex PCR and bidirectional DNA sequencing and the results reported. To maintain patient confidentiality, aliquots of residual DNA material from the diagnostic test were labelled with the LHON mutation detected and irreversibly anonymised. The use of subject DNA in this study has received ethical approval from the Dublin Institute of Technology Research Ethics Committee. This study adhered to the tenets of the Declaration of Helsinki and the ARVO statement on human subjects.

PCR primer sets (Sigma Genosys, Arklow, Ireland, [Table 1](#t1){ref-type="table"}) were designed to produce PCR products only in the presence of the 3460A, 11778A, and 14484C mutations and not in the presence of any of the wild-type sequences. The positions of the primers are highlighted in the complete mitochondrial genome (NCBI Reference Sequence; [NC_012920.1](http://www.ncbi.nlm.nih.gov/nuccore/NC_012920.1)) in Appendix 1. To control for DNA quality and PCR conditions, a control primer set was included that amplifies genomic insulin sequences ([Table 1](#t1){ref-type="table"} and Appendix 2, NCBI Sequence: E00022.1). To clearly differentiate the control and mutation-specific PCR products in a multiplex melt curve analysis, the thermodynamic stability (melting temperature) of the PCR products was initially estimated using uMELT \[[@r34]\] software before experimental analysis in a single tube. All double-stranded DNA sequences have the property that the temperature at which they become single stranded is determined by the sequence composition and the length of the DNA sequence \[[@r35]\]. Several different PCR products can thus be differentiated in a mixture, if the products each have different melting temperatures. The insulin control primer set (INS F/R) was chosen because of its own distinct melting point compared to the three mutations under investigation. A β-globin control primer set was also evaluated but not considered as the melting temperature was not easily distinguishable from that of the LHON mutations.

###### PCR primers used in the diagnostic test.

  Mutation          Primer (5'-3')                     Product size (Position)   Melt temperature average (range)
  ----------------- ---------------------------------- ------------------------- ----------------------------------
  3460**A** ARMS    F: TACTACAACCCTTCGCTGcC**A\***     120 bp (3440--3559)       82.58 °C (82.32 - 83.14)
                    R: GTAGAAGAGCGATGGTGAGAGCTAAG                                 
  11778**A** ARMS   F: ACGAACGCACTCACAGTgA             143 bp (11,760-11902)     80.32 °C (80.08 - 80.7)
                    R: CACAGAGAGTTCTCCCAGTAGGTTAA                                 
  14484**C** ARMS   F: GTAGTATATCCAAAGACAACgA**C\***   161 bp (14,462-14622)     76.31 °C (76.01 - 76.77)
                    R: GGGTTTTCTTCTAAGCCTTCTCC                                    
  Insulin control   F: GACTGAATTCCGGCACGTCCTGGCAGTG    221 bp (1458--1658)       90.24 °C (90.04 - 90.68)
                    R: GACTCTCGAGGGAGGCGGCGGGTGTG                                 

The bases highlighted in bold result in allele specific amplification of the 3460A, 11778A and 14484C mutated sequences respectively. Lower case bases highlight mismatches to increase the specificity of the allele specific amplification. The PCR product sizes, positions in Homo sapiens mitochondrion, complete genome (NCBI Reference Sequence: [NC_012920.1](http://www.ncbi.nlm.nih.gov/nuccore/NC_012920.1)) or genomic insulin sequence (E00022.1) and average melting temperatures are highlighted. The melting temperatures are based on at least 9 separate experiments. The 2 primers marked with \* have previously been published by Bi et al. 2010 \[[@r30]\].

Simplex PCR for the determination of melting temperatures of individual PCR products was performed on an ABI 7500 Fast (Life Technologies, Carlsbad, CA) real-time PCR instrument in a reaction containing 50 ng of genomic DNA, 100 ng of the appropriate primer mix, and 7.5 μl of PowerUp SYBR Green Master Mix (Life Technologies) in a total volume of 15 μl. The PCR conditions were 95 °C for 2 min, followed by 35 cycles of 95 °C for 3 s, and 60.5 °C for 30 s. This was followed by melt curve analysis at 95 °C for 15 s, 60 °C for 1 min, and continuous detection up to 95 °C. For multiplex analysis, these cycling conditions were used on 50 ng of DNA and a primer mix containing 20 ng of 3460 amplification-refractory mutation system (ARMS) F/R, 35 ng of 11,778 ARMS F/R, 250 ng of 14,484 ARMS F/R, and 15 ng of INS F/R. During optimization of the protocol, products were also detected with electrophoresis on a 2.5% agarose gel (Life Technologies) containing 0.5 μg/ml ethidium bromide (catalogue no. E7637; Sigma Genosys, Arklow, Ireland).

Results
=======

The test is designed such that the control sequence will always produce a product, while the presence of one of the mutations will be detected by the additional amplification of the corresponding allele-specific PCR product. The presence of the control PCR product in the absence of any of the mutation-specific PCR products indicates the absence of the three mutations. The presence of the control product in the presence of one of the mutation-specific PCR products indicates the presence of the mutation. The resultant PCR products can be visualized (if required) on an ethidium bromide--stained agarose gel ([Figure 1A](#f1){ref-type="fig"}), but the SYBR green dye and melting curves detect and differentiate the control and allele-specific products in real time. The melting temperatures of the 3460A, 11778A, 14484C, β--globin, and INS control products were 82.58 °C, 80.32 °C, 76.31 °C, 86.03 °C, and 90.24 °C, respectively, allowing clear differentiation of the allele-specific products as shown in [Figure 1B](#f1){ref-type="fig"}. As the melting temperature of the INS product is significantly different from any of the allele-specific products, this product was chosen for the multiplex analysis.

![Melt temperatures of individual PCR products. **A**: 2.5% ethidium bromide stained agarose gel showing the results of simplex PCR amplification of 3460A, 1177A, and 14484C allele--specific products and insulin and control product (1, 2, 3, 4, respectively). **B**: Melt curve generated on ABI 7500 Fast of the same products demonstrating the different melting temperatures of the allele-specific products and the control products. 3460A, 82.58 °C; 11778A, 80.32 °C; 14484C, 76.31 °C; INS, 90.24 °C.](mv-v22-1169-f1){#f1}

Multiplex analysis using a combination of the three allele-specific primer sets and the INS control primer set provided clear and robust detection of the three mutations in the subject control samples as demonstrated in [Figure 2](#f2){ref-type="fig"}. [Figure 3](#f3){ref-type="fig"} shows the four samples on a 2.5% agarose gel and on a real-time melt curve screen, demonstrating the clear differentiation of the allele-specific products using melting temperatures.

![Multiplex real-time analysis of LHON subject samples. **A**: Unmutated DNA; only the control product is amplified. **B**: Subject DNA with mutation in 3460A; products at 90.04 °C and 82.32 °C. **C**: Subject DNA with mutation in 11778A; products at 90.04 °C and 80.12 °C. **D**: Subject DNA with mutation in 14484C mutation; products at 90.04 °C and 76.32 °C.](mv-v22-1169-f2){#f2}

![Multiplex Real time ARMS / High resolution melt PCR.. **A**: 2.5% ethidium bromide stained agarose gel showing the results of multiplex PCR amplification of (1) unmutated DNA and (2--4) subject DNA with mutations in 3460A, 1177A, and 14484C. The control 221 bp Ins PCR product is present in all lanes with the allele-specific products appearing only in the 3460A (120 bp), 1177A (143 bp), and 14484C (161 bp) subject samples. **B**: Multiplex real-time melt curves show clear differentiation of the melt peaks for the control (90. 68 °C), 3460A (82.32 °C), 11,778 (80.12 °C), and 14484C (76.32 °C). All samples produce the control products while the presence of a mutation is detected by the additional allele-specific amplification of the mutation-specific products with a melt temperature at the appropriate temperature.](mv-v22-1169-f3){#f3}

Discussion AND Conclusion
=========================

This study aimed to develop a novel ARMS PCR / high resolution melt curve-based multiplex assay for the detection of the three most common mutations leading to LHON. Approximately 95% of patients with LHON have one of the three common mutations, G3460A (13%), G11778A (69%) and T14484C (14%), with other rare mutations accounting for the final 5%. This assay robustly detected the three primary mitochondrial mutations causing LHON in less than 1 h at a cost that is significantly lower than individual PCR-RFLP \[[@r28]\], multiplex PCR-RFLP \[[@r29]\], bidirectional Sanger sequencing or pyrosequencing sequencing \[[@r32]\], and next-generation sequencing methodologies \[[@r33]\]. This assay provides a significant advantage over current technologies. As can be seen in [Figure 1](#f1){ref-type="fig"} and [Figure 2](#f2){ref-type="fig"}, mutation identification in subjects is clear and robust. This assay could be implemented in any laboratory with a SYBR Green--capable real-time PCR machine and with minimal optimization and setup time. We suggest that the assay described will detect 95% of the mutations that cause LHON at minimal cost with a rapid turnaround time. The genetic testing registry ([NCBI](http://www.ncbi.nlm.nih.gov/gtr/); accessed May 2016) shows that most LHON testing involves uni- or bidirectional Sanger sequencing targeted to the three primary mutations (n = 21), targeted simplex PCR-RFLP (n = 7), and other testing methods (including real-time mutation detection, PCR followed by hybridization and pyrosequencing; n = 4) with two laboratories offering a targeted 37 mitochondrial gene NGS panel (mtSEEK®). The assay described in this manuscript would allow many laboratories testing for LHON to rule out the established mutations 3460A, 11778A, and 14484C in 95% of tests, thus focusing NGS resources on the remaining 5% of test samples.
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Reference mitochondrial genome sequence (NC_012920.1) highlighting the positions of ND1, ND4 and ND6 genes in yellow. Also shown are the positions of the G3460A, G11778A and T14484C mutations (arrows) and the positions of the forward and reverse primers used in the study (red). The sequence was retrieved from NCBI and presented using BioEdit. To access the data, click or select the words "[Appendix 1](http://www.molvis.org/molvis/v22/appendices/mv-v22-1169-app-1.docx)."

Genomic sequence for human pre pro insulin (E00022.1) highlighting the positions the forward and reverse primers used in the study (red). The sequence was retrieved from NCBI and presented using BioEdit. Additional sequences on the 5' end of the primers are used for cloning purposes and contain EcoRI and XhoI restriction sites. To access the data, click or select the words "[Appendix 2](http://www.molvis.org/molvis/v22/appendices/mv-v22-1169-app-2.docx)."
